查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1403495

到 2030 年尿道感染市场预测：按产品类型、治疗类型、测试类型、适应症、分销管道、最终用户和地区进行的全球分析

Urinary Tract Infection Market Forecasts to 2030 - Global Analysis By Product, Treatment Type, Test Type, Indication, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球尿道感染市场规模为 66 亿美元，预计 2030 年将达到 110.7 亿美元，预测期内复合年增长率为 7.67%。

尿道感染是尿液检查，用于检测和管理多种疾病，包括尿道感染、肾臟疾病和糖尿病。尿道感染是一种常见的疾病，主要由进入尿道并在泌尿道内繁殖的细菌所引起。该公司透过提供适合尿道结石管理的诊断工具、抗生素和治疗方法，为医疗保健产业做出贡献。

根据美国家庭医师学会 (AAFP) 莱昂纳多·费雷拉 (Leonardo Ferreira) 2020 年 3 月的报告，肾结石是一种常见疾病，每年每 1000 人中有 8 例发病。根据同一来源，大约 13% 的男性和 7% 的女性在一生中会患上肾结石，而美国闭尿症的总体发生率为每年每 1,000 名男性 4.5 至 6.8 例。

尿道感染增加

尿道感染(UTI) 的盛行率不断上升，特别是在女性、老年人和免疫力人群中，正在推动对诊断和治疗方案的需求。人口老化、对尿道感染感染知识的增加以及对早期发现和及时治疗的日益重视是推动尿道感染市场成长的一些因素。此外，这个市场驱动因素凸显了对新型诊断、抗生素和预防措施的需求，并鼓励对尿道结石新产品和治疗方法的开发进行投资和研究。

抗生素抗药性增加

由于抗生素的过度使用和滥用而导致抗药性细菌的出现，使得尿道感染的有效治疗变得困难。新治疗方法的需求源于这样一个事实：这种抗药性细菌限制了现有抗生素的有效性并使标准治疗方法变得复杂。在尿道结石治疗中对抗抗生素抗药性需要重点研究和开发，以寻找新药和替代治疗方法。

引进新诊断技术

护理点诊断和快速分子检测是先进诊断工具的例子，可以帮助更快、更准确地识别尿道结石。这使得抗生素的有效使用和及时治疗成为可能，从而在人们对抗生素抗药性日益担忧的情况下改善患者照护。投资尿道结石诊断解决方案的公司可以受益于对准确、高效的诊断技术日益增长的需求，改善整体医疗保健结果并提高尿道结石结石治疗的经济效益。您可以减轻负担。

缺乏意识

泌尿器官系统尿道结石是一种影响泌尿系统的常见细菌感染疾病，由于大众对其原因、症状和预防措施了解不足，常常未被发现。这种认知的缺乏阻碍了早期诊断和及时的医疗干预，导致併发症和医疗费用增加。然而，关于卫生习惯的误解和资讯不足导致了尿道结石的流行。缺乏认识不仅会影响个人健康结果，还会对医疗保健系统造成压力。

新冠肺炎 (COVID-19) 影响：

对管理和遏制病毒的关注已经将医疗保健资源、注意力和资金从其他医疗疾病（包括尿道结石）转移开。封锁、获得医疗服务的机会有限以及患者害怕去医疗机构就诊，导致诊断和治疗的延误，加剧了尿道结石的严重程度。此外，增加使用抗生素来治疗与 COVID-19 相关的细菌感染疾病可能会导致抗生素抗药性并限制标准尿道结石治疗的有效性。供应链中断也影响了尿道结石治疗和诊断的可得性。

预计抗生素市场在预测期内将是最大的市场

预计抗生素领域在预测期内将占最大份额。在尿道感染市场的抗生素领域，有多种药物用于治疗细菌性泌尿道感染疾病。 β-内酰胺抗生素（例如阿莫西林）和Fluoroquinolones抗生素（例如Ciprofloxacin）是经常用于治疗尿道感染的抗生素。此外，正在进行的研究和开发的目标是减少副作用、最大限度地减少抗药性并提高这些抗生素的有效性。

预计临床实验室产业在预测期内的复合年增长率最高

尿道感染市场的临床实验室领域预计将出现盈利成长。临床实验室在透过分析尿液样本来识别和确认尿道结石方面发挥着至关重要的作用，包括评估细菌的存在和确定抗生素敏感性。这些实验室利用先进的技术和测试方法来确保准确、及时的结果并促进及时的医疗干预。此外，自动化和分子诊断技术的采用提高了尿道结石诊断的效率和准确性。

占比最高的地区

在医疗成本上升、医疗基础设施改善以及对尿道结石认识提高的背景下，由于对诊断和治疗解决方案的需求，亚太地区的尿道感染市场正在显着扩大。尿道结石发生率的增加也是由于生活型态的改变和老化所造成的。此外，有利的政府措施以及製药和医疗保健公司的成长正在支持该地区的成长。

复合年增长率最高的地区：

在欧洲，由于老年人口的增加和社会意识的提高，尿道感染市场正在显着扩大。糖尿病和尿失禁等危险因子的日益普及也推动了欧洲的成长。此外，政府提高人们对泌尿器官系统健康问题的认识并鼓励采取预防措施的宣传活动正在推动欧盟市场的成长。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球尿道感染市场：依产品

  • Azole和Amphotericin B
  • 头孢菌素
  • 硝基呋喃
  • 青霉素及其组合
  • 奎诺酮
  • 其他产品

第六章全球尿道感染市场：依治疗类型

  • 抗生素
  • 止痛药
  • 解痉药
  • 其他治疗类型

第七章全球尿道感染市场：依测试类型

  • 显微镜下尿道感染
  • 生化尿道感染
  • 流式细胞技术检测尿道感染
  • 其他测试类型

第八章全球尿道感染市场：依适应症分类

  • 复杂性尿道感染
  • 神经源性膀胱感染疾病
  • 復发性复杂性尿道感染
  • 单纯性尿道感染
  • 其他适应症

第九章全球尿道感染感染市场：依分销管道分类

  • 药局
  • 妇科及泌尿系统门诊
  • 零售药房
  • 其他分销管道

第十章全球尿道感染市场：依最终用户分类

  • 医院
  • 临床实验室
  • 家庭保健
  • 其他最终用户

第十一章全球尿道感染市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十二章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章 公司简介

  • Abbott Laboratories
  • Acon Laboratories, Inc.
  • Allergan Plc
  • Arkray, Inc.
  • Astrazeneca Plc
  • Bayer Ag
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • Elektronika Kft.
  • F. Hoffmann-La Roche Ltd
  • Glaxosmithkline Plc
  • Johnson & Johnson
  • Merck & Co. Inc
  • Mindray Medical International Limited
  • Novartis Ag
  • Pfizer Inc
  • Roche Diagnostics
  • Sanofi SA
  • Siemens Healthcare
  • Sysmex Corporation
  • Urit Medical Electronic Group Co., Ltd.
Product Code: SMRC24720

According to Stratistics MRC, the Global Urinary Tract Infection Market is accounted for $6.60 billion in 2023 and is expected to reach $11.07 billion by 2030 growing at a CAGR of 7.67% during the forecast period. Urinary Tract Infections is a test of urine to detect and manage a wide range of disorders, such as urinary tract infections, kidney disease and diabetes. UTIs, caused primarily by bacteria entering the urethra and multiplying in the urinary tract, are common medical conditions. It serves the healthcare sector by providing diagnostic tools, antibiotics, and therapeutics tailored for UTI management.

According to the American Academy of Family Physicians (AAFP), in March 2020, by Leonardo Ferreira, kidney stones were a common ailment, with an annual incidence of eight instances per 1,000 persons. As per the same source, around 13% of men and 7% of women may develop a kidney stone during their lifetime, and the total incidence of urinary retention in the US is 4.5 to 6.8 per 1,000 men per year.

Market Dynamics:

Driver:

Increasing prevalence of urinary tract infections

The increasing prevalence of urinary tract infections (UTIs), especially in women, the elderly, and people with weakened immune systems, is driving up demand for diagnostic and treatment options. The aging population, increased knowledge of UTIs, and a growing emphasis on early detection and timely treatment are some of the factors driving the UTI market's growth. Furthermore, the need for novel diagnostics, antibiotics, and preventive measures is highlighted by this market driver, which encourages investment and research in the creation of fresh goods and remedies for UTIs.

Restraint:

Rising instances of antibiotic resistance

Effective treatment of urinary tract infections is becoming more difficult due to the emergence of resistant bacterial strains caused by the overuse and misuse of antibiotics. The need for new therapeutic solutions arises from the fact that this resistance limits the effectiveness of current antibiotics and complicates standard treatment regimens. In order to combat antibiotic resistance in UTI management, research and development efforts must be concentrated in order to find new medications and alternative treatment modalities.

Opportunity:

Adoption of novel diagnostic technologies

Point-of-care diagnostics and rapid molecular testing are instances of advanced diagnostic tools that can help identify UTIs more quickly and accurately. This helps to effectively use antibiotics, addressing the growing concern of antibiotic resistance, and improves patient care by enabling timely treatment. Businesses that invest in cutting-edge UTI diagnostic solutions will profit from the growing need for accurate and efficient diagnostic techniques, which will enhance overall healthcare outcomes and lessen the financial burden of UTI treatment.

Threat:

Lack of awareness

UTIs, common bacterial infections affecting the urinary system, often go undetected due to insufficient public knowledge about their causes, symptoms, and preventive measures. This dearth of awareness hampers early diagnosis and timely medical intervention, leading to complications and increased healthcare costs. However, misconceptions and inadequate information about hygiene practices contribute to the prevalence of UTIs. The lack of awareness not only affects individual health outcomes but also burdens healthcare systems.

COVID-19 Impact:

The overwhelming focus on managing and containing the virus has diverted healthcare resources, attention, and funding away from other medical conditions, including UTIs. Lockdowns, restricted healthcare access, and patient concerns about visiting medical facilities have led to delayed diagnoses and treatments, exacerbating the severity of UTIs. Moreover, the increased use of antibiotics to treat COVID-19-related bacterial infections has contributed to antibiotic resistance, potentially limiting the effectiveness of standard UTI treatments. Supply chain disruptions have also affected the availability of UTI medications and diagnostics.

The antibiotics segment is expected to be the largest during the forecast period

The antibiotics segment expected to have largest share over the anticipated period. A wide variety of medications are used to treat bacterial infections of the urinary tract in the Urinary Tract Infection market's antibiotics segment. Beta-lactam antibiotics, like amoxicillin, and fluoroquinolones, like ciprofloxacin, are frequently prescribed antibiotics for urinary tract infections. Additionally, the goals of ongoing research and development are to reduce side effects, minimize resistance, and improve the effectiveness of these antibiotics.

The clinical laboratories segment is expected to have the highest CAGR during the forecast period

Clinical laboratories segment in the urinary tract infection market is expected to have profitable growth. Clinical laboratories are pivotal in the identification and confirmation of UTIs through the analysis of urine samples, which includes assessing bacterial presence and determining antibiotic susceptibility. These laboratories utilize advanced technologies and testing methods to ensure accurate and timely results, facilitating prompt medical intervention. Moreover, the adoption of automation and molecular diagnostic techniques within these laboratories enhances the efficiency and precision of UTI diagnostics.

Region with largest share:

The Asia-Pacific Urinary Tract Infection market is expanding substantially due to the need for diagnostic and treatment solutions is being driven by rising healthcare costs, better healthcare infrastructure, and increased awareness of UTIs. The increased frequency of UTIs is also attributed to a changing lifestyle and an aging population. Additionally, favourable government initiatives and the growth of pharmaceutical and healthcare companies are driving the regional growth.

Region with highest CAGR:

The market for urinary tract infections is expanding substantially in Europe due to a growing geriatric population and rising public awareness. The market is growing due to risk factors like diabetes and urine incontinence are becoming more common, which is also driving growth in Europe. Additionally, government campaigns to raise awareness of urinary health issues and encourage preventative measures have been crucial in driving market growth in the European Union.

Key players in the market:

Some of the key players in Urinary Tract Infection market include Abbott Laboratories , Acon Laboratories, Inc., Allergan Plc, Arkray, Inc., Astrazeneca Plc, Bayer Ag , Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Elektronika Kft., F. Hoffmann-La Roche Ltd, Glaxosmithkline Plc, Johnson & Johnson, Merck & Co. Inc, Mindray Medical International Limited, Novartis Ag, Pfizer Inc, Roche Diagnostics, Sanofi S.A., Siemens Healthcare, Sysmex Corporation and Urit Medical Electronic Group Co., Ltd.

Key Developments:

In December 2023, Fujirebio Holdings, Inc. and Sysmex Corporation announced that they have signed an agreement for the mutual supply of reagent raw materials owned by both companies. The Agreement is based on a basic agreement on business collaboration in the field of immunoassay. Under the terms of the Agreement, Fujirebio and Sysmex will mutually supply a wide range of reagent materials owned by each company, mainly antigens and antibodies, which are the main raw materials of immunoassay reagents.

In December 2023, AstraZeneca Pharma India has entered into a Memorandum of Understanding (MoU) with Roche Diagnostics India to enhance diagnostics for breast cancer patients, particularly focusing on refining HER2 diagnostics with the latest advancements. This strategic alliance aligns with AstraZeneca's commitment to advancing patient-centric healthcare solutions and Roche Diagnostics' dedication to pioneering diagnostic innovation.

Products Covered:

  • Azoles and Amphotericin B
  • Cephalosporin
  • Nitrofurans
  • Penicillin and Combinations
  • Quinolones
  • Other Products

Treatment Types Covered:

  • Antibiotics
  • Analgesics
  • Antispasmodics
  • Other Treatment Types

Test Types Covered:

  • Microscopic Urinary Tract Infections
  • Biochemical Urinary Tract Infections
  • Flow Cytometric Urinary Tract Infections
  • Other Test Types

Indications Covered:

  • Complicated Urinary Tract Infection
  • Neurogenic Bladder Infections
  • Recurring Complicated Urinary Tract Infection
  • Uncomplicated Urinary Tract Infection
  • Other Indications

Distribution Channels Covered:

  • Drug Stores
  • Gynaecology and Urology Clinics
  • Retail Pharmacies
  • Other Distribution Channels

End Users Covered:

  • Hospitals
  • Clinical Laboratories
  • Home Healthcare
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Urinary Tract Infection Market, By Product

  • 5.1 Introduction
  • 5.2 Azoles and Amphotericin B
  • 5.3 Cephalosporin
  • 5.4 Nitrofurans
  • 5.5 Penicillin and Combinations
  • 5.6 Quinolones
  • 5.7 Other Products

6 Global Urinary Tract Infection Market, By Treatment Type

  • 6.1 Introduction
  • 6.2 Antibiotics
  • 6.3 Analgesics
  • 6.4 Antispasmodics
  • 6.5 Other Treatment Types

7 Global Urinary Tract Infection Market, By Test Type

  • 7.1 Introduction
  • 7.2 Microscopic Urinary Tract Infections
  • 7.3 Biochemical Urinary Tract Infections
  • 7.4 Flow Cytometric Urinary Tract Infections
  • 7.5 Other Test Types

8 Global Urinary Tract Infection Market, By Indication

  • 8.1 Introduction
  • 8.2 Complicated Urinary Tract Infection
  • 8.3 Neurogenic Bladder Infections
  • 8.4 Recurring Complicated Urinary Tract Infection
  • 8.5 Uncomplicated Urinary Tract Infection
  • 8.6 Other Indications

9 Global Urinary Tract Infection Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Drug Stores
  • 9.3 Gynaecology and Urology Clinics
  • 9.4 Retail Pharmacies
  • 9.5 Other Distribution Channels

10 Global Urinary Tract Infection Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Clinical Laboratories
  • 10.4 Home Healthcare
  • 10.5 Other End Users

11 Global Urinary Tract Infection Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Abbott Laboratories
  • 13.2 Acon Laboratories, Inc.
  • 13.3 Allergan Plc
  • 13.4 Arkray, Inc.
  • 13.5 Astrazeneca Plc
  • 13.6 Bayer Ag
  • 13.7 Beckman Coulter, Inc.
  • 13.8 Bio-Rad Laboratories, Inc.
  • 13.9 Elektronika Kft.
  • 13.10 F. Hoffmann-La Roche Ltd
  • 13.11 Glaxosmithkline Plc
  • 13.12 Johnson & Johnson
  • 13.13 Merck & Co. Inc
  • 13.14 Mindray Medical International Limited
  • 13.15 Novartis Ag
  • 13.16 Pfizer Inc
  • 13.17 Roche Diagnostics
  • 13.18 Sanofi S.A.
  • 13.19 Siemens Healthcare
  • 13.20 Sysmex Corporation
  • 13.21 Urit Medical Electronic Group Co., Ltd.

List of Tables

  • Table 1 Global Urinary Tract Infection Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Urinary Tract Infection Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Urinary Tract Infection Market Outlook, By Azoles and Amphotericin B (2021-2030) ($MN)
  • Table 4 Global Urinary Tract Infection Market Outlook, By Cephalosporin (2021-2030) ($MN)
  • Table 5 Global Urinary Tract Infection Market Outlook, By Nitrofurans (2021-2030) ($MN)
  • Table 6 Global Urinary Tract Infection Market Outlook, By Penicillin and Combinations (2021-2030) ($MN)
  • Table 7 Global Urinary Tract Infection Market Outlook, By Quinolones (2021-2030) ($MN)
  • Table 8 Global Urinary Tract Infection Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 9 Global Urinary Tract Infection Market Outlook, By Treatment Type (2021-2030) ($MN)
  • Table 10 Global Urinary Tract Infection Market Outlook, By Antibiotics (2021-2030) ($MN)
  • Table 11 Global Urinary Tract Infection Market Outlook, By Analgesics (2021-2030) ($MN)
  • Table 12 Global Urinary Tract Infection Market Outlook, By Antispasmodics (2021-2030) ($MN)
  • Table 13 Global Urinary Tract Infection Market Outlook, By Other Treatment Types (2021-2030) ($MN)
  • Table 14 Global Urinary Tract Infection Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 15 Global Urinary Tract Infection Market Outlook, By Microscopic Urinary Tract Infections (2021-2030) ($MN)
  • Table 16 Global Urinary Tract Infection Market Outlook, By Biochemical Urinary Tract Infections (2021-2030) ($MN)
  • Table 17 Global Urinary Tract Infection Market Outlook, By Flow Cytometric Urinary Tract Infections (2021-2030) ($MN)
  • Table 18 Global Urinary Tract Infection Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 19 Global Urinary Tract Infection Market Outlook, By Indication (2021-2030) ($MN)
  • Table 20 Global Urinary Tract Infection Market Outlook, By Complicated Urinary Tract Infection (2021-2030) ($MN)
  • Table 21 Global Urinary Tract Infection Market Outlook, By Neurogenic Bladder Infections (2021-2030) ($MN)
  • Table 22 Global Urinary Tract Infection Market Outlook, By Recurring Complicated Urinary Tract Infection (2021-2030) ($MN)
  • Table 23 Global Urinary Tract Infection Market Outlook, By Uncomplicated Urinary Tract Infection (2021-2030) ($MN)
  • Table 24 Global Urinary Tract Infection Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 25 Global Urinary Tract Infection Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 26 Global Urinary Tract Infection Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 27 Global Urinary Tract Infection Market Outlook, By Gynaecology and Urology Clinics (2021-2030) ($MN)
  • Table 28 Global Urinary Tract Infection Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 29 Global Urinary Tract Infection Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 30 Global Urinary Tract Infection Market Outlook, By End User (2021-2030) ($MN)
  • Table 31 Global Urinary Tract Infection Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 32 Global Urinary Tract Infection Market Outlook, By Clinical Laboratories (2021-2030) ($MN)
  • Table 33 Global Urinary Tract Infection Market Outlook, By Home Healthcare (2021-2030) ($MN)
  • Table 34 Global Urinary Tract Infection Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.